<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00462371</url>
  </required_header>
  <id_info>
    <org_study_id>ASB21004821</org_study_id>
    <nct_id>NCT00462371</nct_id>
  </id_info>
  <brief_title>Comparison Between Insulin Pump Treatment and Multiple Daily Insulin Injections in Diabetic Type 1 Children</brief_title>
  <official_title>Open-Label, Randomised Trial Comparing Efficacy of Continuous Subcutaneous Insulin Infusion(CSII) and Multiple Daily Insulin Injections (MDII) in Improving Glycemic Control and Quality of Life in Poorly Regulated Type 1 Diabetic Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Erasmus Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Erasmus Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison between insulin pump treatment and multiple daily insulin injections in 38&#xD;
      children with type 1 diabetes4-16 years old. Outcome metabolic control, quality of life,&#xD;
      impact of disease and cost effectiveness.&#xD;
&#xD;
      We hypothesised that insulin pump treatment would give a better metabolic control and quality&#xD;
      of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current standard of insulin treatment in type 1 diabetes is multiple daily insulin&#xD;
      injection therapy (MDII). In the seventies, continuous subcutaneous insulin infusion (CSII)&#xD;
      was introduced. CSII has been gaining popularity, perhaps because of technical advances&#xD;
      resulting in improved patient comfort. In children five randomised studies(1-5) were&#xD;
      completed to compare MDII and CSII. No data were gained about quality of life and impact of&#xD;
      disease.&#xD;
&#xD;
      In our trial we focussed on quality of life next to metabolic control.&#xD;
&#xD;
      The trial was an open-labelled,randomised trial. Both efficacy and safety data were&#xD;
      collected. The trial started with a 14 weeks run in phase, during all patients started&#xD;
      MDII.In the following randomisation phase patients were randomised to continue MDII or to&#xD;
      CSII.This phase lasted 14 weeks.In the phase thereafter all patients used CSII for 14 weeks.&#xD;
      The trial was concluded by a 14 weeks allocated patient preference phase.&#xD;
&#xD;
      Patients were type 1 diabetic children 4-16 years old with poor metabolic control.hypothesis:&#xD;
      better metabolic control in CSII, better quality of life in CSII.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2002</start_date>
  <completion_date type="Actual">February 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>metabolic control</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>quality of life</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>cost effectiveness</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>surrogate markers for late complications</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>impact of disease</measure>
  </secondary_outcome>
  <enrollment>38</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Child</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Insulin pump (CSII)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Type 1 diabetes,&#xD;
&#xD;
          -  Diagnosed by the presence of IA-2,&#xD;
&#xD;
          -  GAD-65 or islet cell cytoplasmatic auto antibodies,&#xD;
&#xD;
          -  Daily insulin adminstration or 1 year of longer,&#xD;
&#xD;
          -  Random C-peptide &lt;200 pMol,&#xD;
&#xD;
          -  Hba1c&gt;8.0% and/or a history of repeated symptomatic hypoglycaemias,&#xD;
&#xD;
          -  Attending regular school&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical manifest chronic complications,&#xD;
&#xD;
          -  Pregnancy,&#xD;
&#xD;
          -  Co-morbidity,&#xD;
&#xD;
          -  Mental retardation,&#xD;
&#xD;
          -  Psychiatric treatment or symptoms in child or parent,&#xD;
&#xD;
          -  Insufficient Dutch language capabilities and absence of telephone at home&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>roos Nuboer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Bruining, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Erasmus Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ErasmusMC/Sophia´s children´s Hospital</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 GJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Fox LA, Buckloh LM, Smith SD, Wysocki T, Mauras N. A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes. Diabetes Care. 2005 Jun;28(6):1277-81. doi: 10.2337/diacare.28.6.1277.</citation>
    <PMID>15920039</PMID>
  </reference>
  <reference>
    <citation>Wilson DM, Buckingham BA, Kunselman EL, Sullivan MM, Paguntalan HU, Gitelman SE. A two-center randomized controlled feasibility trial of insulin pump therapy in young children with diabetes. Diabetes Care. 2005 Jan;28(1):15-9. doi: 10.2337/diacare.28.1.15.</citation>
    <PMID>15616227</PMID>
  </reference>
  <reference>
    <citation>Doyle EA, Weinzimer SA, Steffen AT, Ahern JA, Vincent M, Tamborlane WV. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care. 2004 Jul;27(7):1554-8. doi: 10.2337/diacare.27.7.1554.</citation>
    <PMID>15220227</PMID>
  </reference>
  <reference>
    <citation>Weintrob N, Benzaquen H, Galatzer A, Shalitin S, Lazar L, Fayman G, Lilos P, Dickerman Z, Phillip M. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens in children with type 1 diabetes: a randomized open crossover trial. Pediatrics. 2003 Sep;112(3 Pt 1):559-64. doi: 10.1542/peds.112.3.559.</citation>
    <PMID>12949284</PMID>
  </reference>
  <reference>
    <citation>DiMeglio LA, Pottorff TM, Boyd SR, France L, Fineberg N, Eugster EA. A randomized, controlled study of insulin pump therapy in diabetic preschoolers. J Pediatr. 2004 Sep;145(3):380-4. doi: 10.1016/j.jpeds.2004.06.022.</citation>
    <PMID>15343195</PMID>
  </reference>
  <verification_date>April 2007</verification_date>
  <study_first_submitted>April 18, 2007</study_first_submitted>
  <study_first_submitted_qc>April 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 19, 2007</study_first_posted>
  <last_update_submitted>April 18, 2007</last_update_submitted>
  <last_update_submitted_qc>April 18, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 19, 2007</last_update_posted>
  <keyword>quality of life</keyword>
  <keyword>child diabetes mellitus type 1</keyword>
  <keyword>Continuous subcutaneous insulin infusion(CSII)</keyword>
  <keyword>metabolic control</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

